Venture CapitalCytospire raises £61M to take gamma-delta T-cell engager into the clinicCytospire Therapeutics has raised a £61 million (€71 million) Series A round, positioning the British biotech to advance pan-gamma-delta T-cell engagers (TCEs) into cancer clinical trials. more ➔
M&AUCB buys Candid Therapeutics for up to US$2.2bn to deepen autoimmune T-cell engager pushBelgian biopharma UCB has moved quickly from testing the waters in autoimmune T-cell engagers to making one of the largest bets yet on the modality, agreeing to acquire San Diego-based Candid Therapeutics … more ➔
Planet Volumes via Unsplash+FinancingBioOrbit: record seed round for in‑space drug manufacturingCan in‑space manufacturing help cancer patients take complex medicines at home? For a technology that aims to do just that, UK‑based BioOrbit has just raised £9.8m (around €11.3m) – the “world’s … more ➔
ValnevaFinancingValneva reels in €84m in fresh financing to shore up vaccine pipelineValneva SE, the French specialty‑vaccine developer, has completed an €84m reserved offering, adding a useful cash buffer just as the group enters a high‑risk window for its Lyme disease and shigellosis‑vaccine … more ➔
ServierVenture CapitalInside Servier’s new €200M venture fundWith the launch of Servier Ventures announced in January and a €200 million commitment to biotech investment, Servier is stepping up its engagement in early-stage innovation in oncology and neurology. … more ➔
Paris Bilal via Unsplash+AcquisitionChiesi in US$1.9bn deal to buy KalVista and its angioedema drugItalian pharma group Chiesi has struck a near‑US$1.9bn deal to acquire KalVista Pharmaceuticals, bringing the US biotech’s first‑in‑class oral treatment for hereditary angioedema into its rare‑disease … more ➔
A. C. via Unsplash+FinancingCoultreon bags US$125m for autoimmune pipelineBelgian Coultreon Biopharma has raised US$125m in a big‑pharma‑backed Series A round to push its first‑in‑class SIK3 inhibitor into Phase II after an ongoing Phase I programme in autoimmune … more ➔
Pic by masakazu sasaki via UnsplashAcquisitionAstorg spins off Thermo Fisher’s microbiology armPan-European private‑equity firm Astorg has agreed to acquire Thermo Fisher Scientific’s global microbiology business for about US$1.08bn, carving it out into a standalone platform focused on antimicrobial … more ➔
Andrej Lišakov / Unsplash+Covid-19CureVac takes Moderna to court over mRNA vaccine patentsCureVac has filed a federal lawsuit accusing Moderna of patent infringement over its mRNA-based COVID-19 vaccine Spikevax. The German biotech claims that Moderna used its proprietary methods for stabilising … more ➔
Evonik Industries AGInvestmentEvonik: €80m for biopharma CDMO capacity in SlovakiaEvonik is investing €80 million in its fermentation plant in Slovakia, pushing the Group’s structural transformation forward with a major investment in biotechnology. Alongside spider‑silk proteins … more ➔
Planet Volumes via Unsplash+
Valneva
Servier
Paris Bilal via Unsplash+
A. C. via Unsplash+
Pic by masakazu sasaki via Unsplash
Andrej Lišakov / Unsplash+
Evonik Industries AG